Caribou Biosciences

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases. They leverage their next-generation CRISPR genome-editing technology, called chRDNA, which enables superior specificity and precision for complex genome editing. Caribou is developing "off-the-shelf" CAR-T cell therapies derived from healthy donor cells, aimed at addressing the limitations of currently approved therapies. Their approach involves "armoring" these allogeneic CAR-T cells through multiple genome-editing strategies, including checkpoint disruption and immune cloaking, to enhance their activity against diseases.

Caribou's pipeline includes several clinical-stage programs targeting hematologic malignancies and autoimmune diseases. Their lead program, CB-010, is an allogeneic anti-CD19 CAR-T cell therapy for the treatment of relapsed or refractory B cell non-Hodgkin lymphoma. They are also developing CB-011, an allogeneic anti-BCMA CAR-T cell therapy for multiple myeloma, and CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for acute myeloid leukemia. Caribou's commitment to innovation and their advanced genome editing technology positions them as a leader in the rapidly growing field of cell therapy.

Caribou Biosciences does not mention any specific job flexibility options on their website.

Caribou Biosciences offers a comprehensive benefits package to eligible employees, including health insurance (medical, dental, vision), a 401(k) plan with a 4% employer match, pre-tax spending plans, life insurance, short-term and long-term disability insurance, employee wellness programs, tuition reimbursement, paid time off, a gym membership discount, on-site parking, commuter benefits, and electric vehicle charging access.

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative, genome-edited allogeneic cell therapies for devastating human diseases. Their proprietary chRDNA technology, a next-generation CRISPR system, enables superior specificity and precision in genome editing. Caribou is pioneering off-the-shelf cell therapies, specifically CAR-T cell therapies, derived from healthy donor cells to address the limitations of currently approved therapies. Their mission is to unlock the full potential of these allogeneic cell therapies by utilizing their chRDNA technology to "armor" them with multiple genome-editing strategies, including checkpoint disruption and immune cloaking, ultimately enhancing their activity against debilitating diseases.

Caribou Biosciences cultivates a collaborative and innovative culture where diversity of thought and background is valued. They emphasize the importance of employee engagement, recognizing contributions, and meeting individual needs, all while being driven by a shared commitment to patient need and the potential of their chRDNA technology. Caribou promotes a strong work ethic focused on translating their groundbreaking technologies into life-changing therapies.

Caribou Biosciences is committed to fostering a culture of diversity, equity, and inclusion (DEI), recognizing that diverse teams perform better and are more innovative. They strive to create an inclusive environment where everyone feels valued and respected, regardless of their age, background, identity, or other personal characteristics. This commitment is reflected in their recruiting practices and ongoing efforts to build a workforce that reflects the diverse communities they serve.